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Abstract
Objective and design T helper 17 (Th17) and regulatory
T (Treg) lymphocytes might play important roles in patients
with severe sepsis. The association of Th17 or Treg lym-
phocytes with survival is also unclear.
Methods Eighty-seven patients with severe sepsis were
enrolled from our intensive care units between August
2008 and July 2010. Leukocyte antigens and clinical data
were determined on day 1 in all patients and on day 7 in
first-year patients.
Results The percentages in peripheral blood mononuclear
cells (PBMCs) and circulatory counts of CD4? and CD8?
lymphocytes in survivors were higher than those in non-
survivors. Th1/CD4? ratios and circulatory Th1 lympho-
cyte counts in survivors were higher than in non-survivors.
Absolute counts of Th17 and Treg lymphocytes in survivors
were higher than in non-survivors. The percentages of
CD4? and CD8? in survivors’ PBMCs were increased after
6 days. Th17/CD4? ratios and circulatory Th17 lympho-
cyte counts in survivors were increased after 6 days.
Conclusions Higher Th1 differentiation and total CD4? T
lymphocyte counts were associated with higher survival.
The association of circulatory Th17 and Treg lymphocytes
with mortality in severe sepsis may be due to the change in
total CD4? T lymphocytes. In survivors, Th17 differenti-
ation and counts were restored.
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Introduction
The majority of clinical and basic studies on sepsis have
focused on the balance between the function of T helper 1
(Th1) and Th2 cells. The presence of interleukin (IL)-12
with signaling through signal transduction and activator of
transcription (STAT)-4 skews towards Th1, whereas the
presence of IL-4 with signaling through STAT-6 skews
towards Th2. Th1 cells generally secrete pro-inflammatory
cytokines such as interferon (IFN)-c, tumor necrosis factor
(TNF)-a and IL-1b, and Th2 cells generally have an
important impact on allergic/atopic disorders and the
humoral immune response. In patients with sepsis, the
median Th1/Th2 ratio was lower [1]. This suggests that
activated T helper cells evolve from the Th1 phenotype to
the Th2 phenotype in patients with severe sepsis or that
patients with low Th1/Th2 ratios develop sepsis more
easily.
However, naı¨ve CD4? T helper cells can be induced to
differentiate towards Th1, Th2, Th17 and regulatory T
(Treg) phenotypes according to the local cytokine milieu [2].
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The presence of IL-6 and transforming growth factor
(TGF)-b skews towards Th17 [3], and that of TGF-b skews
towards Treg cells [4]. Th17 cells can produce IL-17, which
acts in vitro and in vivo as a potent inflammatory cytokine
[5]. Treg cells have several subsets, including naturally
occurring Treg cells, induced Treg cells, Tr1 cells and Th3
cells with CD4?CD25? expression [6, 7].
Tr1 cells produce high levels of IL-10 and Th3 cells
secrete large amounts of TGF-b. In addition, Treg cells have
the ability to suppress the proliferation of T cells [8]. In a
mouse model of sepsis, adoptive transfer of in-vitro-
stimulated Treg cells significantly improved bacterial
clearance, which resulted in improved survival [9]. This
was associated with increased TNF-a production in the
peritoneum. In another mouse model, the administration of
anti-CD25 antibody 3 days before sepsis induced by cecal
ligation and puncture reduced the early lethality [10].
These conflicting results indicate that the precise mecha-
nism involved in sepsis remains to be established. In
contrast to the traditional concept of Th1/Th2 balance, a
new model of pro-inflammatory cells (Th1 and Th17) and
anti-inflammatory cells (Th2 and Treg) is emerging.
Fig. 1 Flow cytometry of cells
from a sepsis patient. CD4
lymphocytes were identified
with positive CD3 and CD4 (a).
CD8 lymphocytes were
identified with positive CD3 and
CD8 (b). Cells in d are gated in
area K in c. Th1 cells were
identified with positive CD4 and
IFN-c, and negative IL-4 (d).
Th2 cells were identified with
positive CD4 and IL-4, and
negative IFN- c. Cells in f are
gated in area A in e. Th17 cells
were identified with positive
CD4 and IL-17, and negative
CD25 (f). Regulatory T cells
were identified with positive




The role of Th17 and Treg lymphocytes in the patho-
genesis of severe sepsis is unknown. The association of
Th17 or Treg lymphocytes with survival or septic shock is
also unclear. Thus, we designed this study to determine the




From August 2008 to July 2010, 87 patients who were
admitted to our intensive care unit (ICU) due to severe
Table 1 Clinical characteristics of survivors, non-survivors and controls
Survivors (n = 60) Non-survivors (n = 27) Controls (n = 30)
Age (years) 71.6 ± 1.8 74.8 ± 2.0 60.7 ± 1.9*
Males 37 (62 %) 15 (56 %) 22 (73)
APACHE II score 24.8 ± 0.9 29.5 ± 1.4*
WBC (/ll) 16,351.7 ± 863.7 16,063.0 ± 1667.4 5,783.3 ± 281.1*
Lymphocytes (%) 8.5 ± 1.2 10.4 ± 2.5 38.3 ± 2.2*
Lymphocytes (/ll) 1,233.2 ± 154.1 1,553.3 ± 435.4 2,140.3 ± 121.6*
History
COPD 12 (20 %) 5 (19 %)
Heart failure 5 (8 %) 0 (0 %)
Pneumoconiosis 3 (5 %) 3 (11 %)
Bronchiectasis 2 (3 %) 0 (0 %)
Hypertension 25 (42 %) 9 (33 %)
Diabetes mellitus 22 (37 %) 9 (33 %)
Previous CVA 22 (37 %) 7 (26 %)
End stage renal disease 6 (10 %) 4 (15 %)
Liver cirrhosis 2 (3 %) 4 (15 %)
Active malignancy 5 (8 %) 6 (22 %)
Infection source
Pneumonia 51 (85 %) 22 (81 %)
Urinary tract infection 7 (12 %) 0 (0 %)
Others 2 (3 %) 5 (19 %)
Initial antibiotics for pathogens
Sensitive 32 (53 %) 16 (59 %)
Resistant 16 (27 %) 11 (41 %)
No pathogen isolated 12 (20 %) 0 (0 %)
Adverse event
New arrhythmia 4 (7 %) 3 (11 %)
Gastrointestinal bleeding 12 (20 %) 4 (15 %)
Acute renal failure 25 (42 %) 16 (59 %)
Shock 34 (57 %) 21 (78 %)
Thrombocytopenia 16 (27 %) 12 (44 %)
Jaundice 2 (3 %) 5 (19 %)*
Bacteremia 12 (20 %) 8 (30 %)
Data are presented as number (%) or mean ± standard error of the mean
APACHE Acute Physiology and Chronic Health Evaluation, WBC white blood cell count, COPD chronic obstructive pulmonary disease, CVA
cerebral vascular accident
* p \ 0.05 compared with survivors by the Mann–Whitney test
 p \ 0.05 compared with non-survivors by the Mann–Whitney test
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sepsis were enrolled into this study. Patients with high-dose
steroids, immunosuppressive medication or post-chemo-
therapy were excluded. To validate the experimental
findings, 30 persons who visited our health evaluation
center for examinations were enrolled as healthy controls.
Severe sepsis was defined according to the consensus cri-
teria [11, 12]. Systemic inflammatory response syndrome
(SIRS) was defined as two or more of the following cri-
teria: (1) body temperature [38 C or \36 C; (2)
respiratory rate [20 breaths/min; (3) heart rate [90 beats/
min; and (4) white blood count (WBC) [12,000/ll or
\4,000/ll or [10 % bands. Sepsis was defined as SIRS
with infection. Severe sepsis was defined as sepsis with one
or more sepsis-induced organ dysfunctions, such as shock,
respiratory failure, acute renal failure, jaundice and
thrombocytopenia. Septic shock was defined as sepsis-
induced hypotension (mean artery pressure \70 mmHg)
unresponsive to fluid resuscitation. Respiratory failure was
defined as ventilation dysfunction with the need of invasive
ventilator support. Acute renal failure was defined as a
rapid increase in creatinine level ([0.5 mg/dl). Jaundice
was defined as hyperbilirubinemia (total bilirubin [2 mg/
dl). Thrombocytopenia was defined as a platelet count
below 150,000/ll. Disease severity was assessed with the
acute physiology and chronic health evaluation (APACHE)
II score [13]. Standard treatment according to guidelines
(Surviving Sepsis Campaign) was provided to all patients
[12, 14]. The informed consent was provided from a close
family member. This investigation (96-1465B, 97-2179B,
98-3511B) was approved by the Institutional Review Board
at Chang Gung Memorial Hospital. Patients who survived
for more than 28 days after admission to our ICU were
defined as survivors. All co-morbidities and past histories
of the subjects were recorded.
Peripheral blood mononuclear cell (PBMC) preparation
Whole blood (10 ml) was obtained within 48 h of admis-
sion to the ICU at 08:00 a.m. from each subject and
immediately mixed with heparin. The day of first blood
sampling was defined as day 1. Patients enrolled from July
2008 to June 2009 were sampled again after 6 days. The
Fig. 2 The percentages of CD4? and CD8? lymphocytes in PBMCs
of survivors were significantly higher than that of non-survivors. The
percentages of CD4? and CD8? lymphocytes in PBMCs of survivors
and non-survivors were significantly lower than that of controls. The
circulatory counts of CD4? and CD8? lymphocytes in survivors were
also higher than that in non-survivors. The circulatory counts of
CD4? and CD8? lymphocytes in survivors and non-survivors were
lower than that in controls. *p \ 0.05 compared with controls,
**p \ 0.05 compared with non-survivors
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PBMCs were isolated via differential centrifugation over
Ficoll-Plaque (Amersham Biosciences, Uppsala, Sweden)
from whole blood within 2 h of collection.
Flow cytometric analysis of PBMCs
2.5 9 105 PBMCs were suspended in 50 ll of phosphate-
buffered saline (PBS) and incubated in the dark for 15 min
at room temperature with 20 ll of Tritest reagent
(CD4FITC, CD8PE, CD3PerCP) (Becton–Dickinson, CA,
USA). The cells were then resuspended in 500 ll of PBS.
The CD4 (CD3?CD4?) and CD8 (CD3?CD8?) lympho-
cytes were detected by a three-color flow cytofluorimeter
(Beckman Coulter, CA, USA) (Fig. 1a, b).
2.5 9 105 PBMCs were stimulated in vitro by 5 lg/ml
phytohemagglutinin (PHA) in 1 ml sterile RPMI1640
(Gibco, Grand Island, USA) tissue culture medium con-
taining 5 % heat-inactivated bovine serum and 1 mM
sodium pyruvate (Gibco). The cells were cultured for 4 h at
37 C and 5 % CO2. The cells were then suspended in
50 ll of PBS and incubated in the dark for 15 min at room
temperature with 20 ll of CD4PerCP antibody. The cells
were added to 500 ll of permeabilizing solution (Becton–
Dickinson, CA, USA) and 10 lg/ml of brefeldin A (Sigma,
Missouri, USA). The cells were incubated for 10 min in the
dark at room temperature after vortexing. The cells were
washed with PBS containing 0.5 % bovine serum albumin
and 0.1 % NaN3, and then incubated with antibodies (anti-
IFN-cFITC and anti-IL-4PE) (Becton–Dickinson). Finally,
the cells were resuspended in 500 ll of PBS. Type 1 Th1-
like (CD4?IFN-c?) and Th2-like (CD4?IL-4?) lympho-
cytes were detected by a three-color flow cytofluorimeter
(Beckman Coulter) (Fig. 1c, d).
2.5 9 105 PBMCs were stimulated in vitro by 5 lg/ml
PHA in 1 ml sterile RPMI1640 (Gibco) tissue culture
medium containing 5 % heat-inactivated bovine serum and
1 mM sodium pyruvate (Gibco). The cells were cultured
for 4 h at 37 C and 5 % CO2. The cells were then
Fig. 3 Th1/CD4? ratios and circulatory Th1 lymphocytes counts
were significantly higher in survivors than in non-survivors. Th1/
CD4? ratios and circulatory Th1 lymphocytes counts were lower in
non-survivors than in controls. Circulatory Th1 lymphocytes counts
in survivors were lower than in controls and there was no difference
in Th1/CD4? ratio between survivors and controls. Th2/CD4? ratio in
non-survivors was higher than in controls. Although median Th2/
CD4? ratio in non-survivors was higher than in survivors, the
difference was not significant. The difference in Th2/CD4? ratio was
similar between survivors and controls. Circulatory Th2 lymphocyte
counts in survivors and non-survivors were lower than in controls.
Circulatory Th2 lymphocyte counts were similar between survivors
and non-survivors. *p \ 0.05 compared with controls, **p \ 0.05
compared with non-survivors
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suspended in 50 ll of PBS and incubated in the dark for
15 min at room temperature with 20 ll of CD4PerCP and
CD25FITC antibodies (Becton–Dickinson). The cells were
added to 500 ll of permeabilizing solution and 10 lg/ml of
brefeldin A. The cells were incubated for 10 min in the
dark at room temperature after vortexing. The cells were
washed with PBS containing 0.5 % bovine serum albumin
and 0.1 % NaN3, and then incubated with antibodies (anti-
IL-17APE) (eBioscience, CA, USA). Finally, the cells
were resuspended in 500 ll of PBS. According the refer-
ences [15, 16], CD4?CD25?high T cells were considered as
Treg cells. Treg (CD4
?CD25?high) and Th17 (CD4?IL-
17A?) lymphocytes were detected by a three-color flow
cytofluorimeter (Beckman Coulter) (Fig. 1e, f).
Calculation of absolute cell counts
Absolute cell counts were the sum of total monocytes and
lymphocytes times each cell percentage of PBMCs. Total
monocytes and lymphocytes were obtained from WBC and
WBC differential counts in the hospital hematologic study.
Statistical analysis
Statistical analysis was performed with SPSS software
v11.0.1 for Windows (SPSS Inc., IL, USA). The Kol-
mogorov–Smirnov test was used to test normal distribution.
Differences in continuous variables between two groups
were analyzed by the Mann–Whitney test. Differences in
categorical variables between two groups were compared
by the chi-squared test or Fisher’s exact test. Differences in
continuous variables in the same subjects were analyzed
using the Wilcoxon signed-rank test. A p value less than
0.05 was considered statistically significant.
Results
Table 1 shows the clinical characteristics among survivors,
non-survivors and healthy controls. The adverse event
percentage of jaundice in non-survivors was significantly
higher than that in survivors. There were no differences in
percentages of new arrhythmia, gastrointestinal bleeding,
Fig. 4 Compared with non-survivors, survivors had significantly
higher circulatory counts of Th17 and Treg lymphocytes. Th17/CD4
?
and Treg/CD4
? ratios in survivors were similar to those in non-
survivors. Th17/CD4? ratio and circulatory Th17 lymphocyte counts
in survivors and non-survivors were higher and lower, respectively,
than in controls. There was no difference in Treg/CD4
? ratio among
survivors, non-survivors and controls. Treg lymphocyte counts in
survivors and non-survivors were lower than in controls. *p \ 0.05
compared with controls, **p \ 0.05 compared with non-survivors
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acute renal failure, shock, thrombocytopenia and bactere-
mia. The APACHE II score in non-survivors was higher
than that in survivors. Age, male/female ratio, histories,
infection source and susceptibility of initial antibiotics for
pathogens in survivors were similar to those in non-survi-
vors. Age and WBC in healthy controls were significantly
lower than those in survivors and non-survivors. Lym-
phocyte percentage and lymphocyte count in healthy
controls were significantly higher than those in survivors
and non-survivors.
Cell analysis among survivors, non-survivors
and controls
The percentages of CD4? and CD8? lymphocytes in
PBMCs of survivors were significantly higher than those of
non-survivors (Fig. 2). The percentages of CD4? and
CD8? lymphocytes in PBMCs of survivors and non-sur-
vivors were significantly lower than those of controls. The
circulatory counts of CD4? and CD8? lymphocytes in
survivors were also higher than those in non-survivors. The
circulatory counts of CD4? and CD8? lymphocytes in
survivors and non-survivors were lower than those in
controls.
Th1/CD4? ratios and circulatory Th1 lymphocytes
counts were significantly higher in survivors than in non-
survivors (Fig. 3). Th1/CD4? ratios and circulatory Th1
lymphocytes counts were lower in non-survivors than in
controls. Circulatory Th1 lymphocytes counts in survivors
were lower than those in controls and there was no dif-
ference in Th1/CD4? ratios between survivors and
controls. Th2/CD4? ratios in non-survivors were higher
than those in controls. Although the median Th2/CD4?
ratio in non-survivors was higher than that in survivors, the
difference was not significant. The difference in Th2/CD4?
ratio was similar between survivors and controls. Circula-
tory Th2 lymphocyte counts in survivors and non-survivors
were lower than those in controls. Circulatory Th2
Fig. 5 The percentages of CD4? lymphocytes in PBMCs of survi-
vors were significantly increased after 6 days. However, circulatory
CD4? lymphocyte counts in survivors did not increase after 6 days.
The CD4? lymphocyte percentages and counts in non-survivors did
not change after 6 days. *p \ 0.05 compared with day 7
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lymphocyte counts were similar between survivors and
non-survivors.
Compared with non-survivors, survivors had signifi-
cantly higher circulatory counts of Th17 and Treg
lymphocytes (Fig. 4). Th17/CD4? and Treg/CD4
? ratios in
survivors were similar to those in non-survivors. Th17/
CD4? ratios and circulatory Th17 lymphocyte counts in
survivors and non-survivors were higher and lower,
respectively, than those in controls. There was no differ-
ence in Treg/CD4
? ratios among survivors, non-survivors
and controls. Treg lymphocyte counts in survivors and non-
survivors were lower than those in controls.
Cell analysis in survivors and non-survivors
between day 1 and day 7
From July 2008 to August 2009, 35 patients were enrolled.
Twenty-three patients survived, six patients died with
7 days, and six patients died within 8–28 days. The
percentages of CD4? lymphocytes in PBMCs of survivors
were significantly increased after 6 days (Fig. 5). However,
circulatory CD4? lymphocyte counts in survivors did not
increase after 6 days. The CD4? lymphocyte percentages
and counts in non-survivors did not change after 6 days.
The percentages of CD8? lymphocytes in PBMCs of sur-
vivors were significantly increased after 6 days (Fig. 6).
Circulatory CD8? lymphocyte counts in survivors did not
increase after 6 days. The CD8? lymphocyte percentages
and counts in non-survivors did not change after 6 days.
Th1/CD4? ratios and circulatory Th1 lymphocyte
counts in survivors and non-survivors did not change after
6 days (Fig. 7). Th2/CD4? ratios and circulatory Th2
lymphocyte counts in survivors and non-survivors also did
not change after 6 days (Fig. 8). However, Th17/CD4?
ratios and circulatory Th17 lymphocyte counts in survi-
vors were significantly increased after 6 days (Fig. 9).
Th17/CD4? ratios and circulatory Th17 lymphocyte
counts between day 1 and day 7 were similar in non-
Fig. 6 The percentages of CD8? lymphocytes in PBMCs of survi-
vors were significantly increased after 6 days. Circulatory CD8?
lymphocyte counts in survivors did not increase after 6 days. The
CD8? lymphocyte percentages and counts in non-survivors did not




? ratios and Treg lymphocyte counts in
survivors and non-survivors did not change after 6 days
(Fig. 10).
Discussion
We found that the circulatory Treg lymphocyte counts on
day 1 in survivors with severe sepsis were higher than
those in non-survivors. This result is similar to the study of
Hein et al. [17], who found that survivors with septic shock
had consistently higher Treg lymphocyte counts than non-
survivors. These findings indicate a specific role of Treg
lymphocytes in patients with severe sepsis. The Treg/CD4
?
percentages on day 1 were similar between survivors and
non-survivors in this work. This might suggest that the Treg
differentiation from naı¨ve CD4? T helper lymphocytes was
similar between survivors and non-survivors. However,
CD4? lymphocyte counts in survivors were higher than
those in non-survivors on day 1. Furthermore, serial Treg/
CD4? percentages and circulatory Treg lymphocyte counts
in survivors and non-survivors did not differ between day 1
and day 7. These results indicate that the benefit of higher
circulatory Treg lymphocyte counts in survivors may be due
to higher circulatory CD4? lymphocyte counts.
Nascimento et al. [18] reported that treatment of mice
with antibody for Treg cells reduced the frequency of Treg
cells, restored CD4? T-cell proliferation, reduced the levels
of bacteria in spleen, and markedly improved survival in
Legionella pneumophila infection. Compared with non-
survivors with severe sepsis, survivors had higher Treg,
Th1, Th17 and total CD4? lymphocyte counts in this work.
Our results differ from Nascimento et al.’s study. Patients
with lower Treg cells did not have higher CD4
? T cells in
severe sepsis. Perhaps Nascimento et al.’s research inves-
tigated the role of Treg cells in the immune response to
secondary infection and our study analyzed a primary
infection. Plasma IL-6 level in survivors with severe sepsis
was lower than that in non-survivors [19, 20]. In this work,
total Treg cells in survivors were higher. Addition of human
Treg cells to polymorphonuclear neutrophil suspension
resulted in a significant decrease of IL-6 production [21].
Thus, lower plasma IL-6 levels in survivors may be due to
higher Treg cell counts.
Fig. 7 Th1/CD4? ratios and circulatory Th1 lymphocyte counts in survivors and non-survivors did not change after 6 days
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Th17 lymphocytes play an important role in inflamma-
tion and host defense [22]. The preoperative expression of
IL-17 mRNA from PBMCs was significantly lower in
patients who developed sepsis after radical cystectomy
[23]. This work first found that the circulatory Th17 lym-
phocyte counts on day 1 in survivors with severe sepsis
were higher than those in non-survivors. Again, the higher
circulatory Th17 lymphocyte counts may relate to higher
CD4? lymphocyte counts in survivors because Th17/CD4?
percentages between survivors and non-survivors were
similar. Serial cell analysis also found that not only Th17/
CD4? percentages but also circulatory Th17 lymphocyte
counts in survivors were significantly increased after
6 days. Based on the above results, we can reasonably
hypothesize important roles of total CD4? lymphocyte
counts and Th17 lymphocyte differentiation in helping
survival in severe sepsis.
Lymphocyte apoptosis is increased in CD4? and CD8?
T cells in sepsis as compared to non-sepsis patients [24].
The CD4? cells might facilitate the early clearance of
bacteria by regulating neutrophil function, possibly through
an IFN-c-dependent mechanism [25]. Thus, patients with
severe sepsis might benefit from increased CD4? and
CD8? lymphocytes. However, the CD4? and CD8? T-cell
counts in non-survivors with severe sepsis after major
surgery were approximately twice as high as those in sur-
vivors [26]. Monserrat et al. [27] did not find a difference
in CD3?CD4? and CD3?CD8? cell counts on ICU
admission day between survivors and non-survivors with
septic shock. These findings are in significant contrast to
our results. In this work, the percentages and circulatory
cell counts of CD4? and CD8? lymphocytes in survivors
were higher than those in non-survivors on day 1. Fur-
thermore, CD4? and CD8? lymphocyte percentages in
PBMCs of survivors were significantly increased after
6 days. More CD4? T lymphocytes may help patients with
severe sepsis to survive. Our results were also similar to
Chen et al.’s study [28]. They found that the percentage of
CD4? T lymphocytes in PBMCs was lower in the non-
survivors with septic shock, compared with the survivors.
Fig. 8 Th2/CD4? ratios and circulatory Th2 lymphocyte counts in survivors and non-survivors did not change after 6 days
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There was no difference in the percentage of CD8? T
lymphocytes between the non-survivor and survivor
groups. Based on the above findings, the low CD4? and
CD8? lymphocyte counts may be a consequence of severe
sepsis but also suggest a pre-existing condition of low
CD4? lymphocyte counts tending to give a poor outcome.
In this work, non-survivors were associated with lower
Th1/CD4? and circulatory Th1 lymphocyte counts at the
same time. These results were similar to the concept that
lack of a shift from Th1 to Th2 response increases survival
among patients with sepsis [29]. Unlike those studies
measuring Th1 (IFN-c or TNF-a) and Th2 (IL-4 or IL-10)
cytokine levels [19, 20, 30, 31], our study directly mea-
sured T-cell phenotypes and first demonstrated that
increased Th1 lymphocyte differentiation was associated
with greater survival.
There was one limitation in this work. Although the CD25
molecule is expressed on all activated peripheral CD4? T
cells, Treg cells were detected with CD4
? and high CD25?
expression [32], not with CD4? and positive forkhead box P3
(Foxp3). Naturally occurring and induced Treg cells express
the signal transduction molecule, Foxp3, and the level of
Foxp3 expression in T cells is related to the Treg-suppressive
activity [33]. However, Foxp3 expression in humans, unlike
mice, may not be specific for cells with a regulatory phe-
notype and may be only a consequence of activation status
[34]. Even though CD4?CD25?high cells are not specific for
Treg cells, CD4
?CD25?high cells could be regarded as Treg
cells in part.
In conclusion, this work showed that Treg lymphocytes
were not directly associated with mortality in severe
sepsis. High circulatory Th17 and Treg lymphocyte counts
in survivors might be due to high numbers of CD4?
lymphocytes. Increased Th17 differentiation might be
associated with survival in patients with severe sepsis.
Under present support systems and treatment guidelines,
total CD4? cell counts play a role influencing the mor-
tality of sepsis patients and a trend toward to Th1
differentiation might help patients with severe sepsis to
survive.
Fig. 9 Th17/CD4? ratios and circulatory Th17 lymphocyte counts in survivors were significantly increased after 6 days. Th17/CD4? ratios and
circulatory Th17 lymphocyte counts were similar between day 1 and day 7 in non-survivors. *p \ 0.05 compared with day 7
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